Bilirubin has potent biological beneficial effects, protecting against atherosclerosis, obesity, and metabolic syndrome. The aim of this study was to assess serum bilirubin concentrations and (TA) and (GT) microsatellite variations in the promoter regions of the and genes, respectively, in patients with type 2 diabetes mellitus (T2DM). The study was carried out in 220 patients with T2DM and 231 healthy control subjects, in whom standard biochemical tests were performed. The (TA) and (GT) dinucleotide variations were determined by means of fragment (size-based) analysis using an automated capillary DNA sequencer. Compared to controls, both male and female patients with T2DM had lower serum bilirubin concentrations (9.9 vs. 12.9 μmol/L, and 9.0 vs. 10.6 μmol/L, in men and women, respectively, < 0.001). Phenotypic Gilbert syndrome was much less prevalent in T2DM patients, as was the frequency of the (TA) genotype in male T2DM patients. (GT) genetic variations did not differ between diabetic patients and controls. Our results demonstrate that the manifestation of T2DM is associated with lower serum bilirubin concentrations. Consumption of bilirubin due to increased oxidative stress associated with T2DM seems to be the main explanation, although (TA) repeat variations in partially contribute to this phenomenon.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10342136 | PMC |
http://dx.doi.org/10.3390/ijms241310614 | DOI Listing |
Xenobiotica
January 2025
Department of Pediatrics, Shiga University of Medical Science, Shiga, Japan.
1. Dolutegravir (DTG) is a key drug used to treat human immunodeficiency virus type-1 (HIV-1) infections. Adverse events (AEs) of DTG treatment, including headache, anxiety, depression, insomnia, and abnormal dreams, are influenced by sex, body weight, age, and serum bilirubin levels.
View Article and Find Full Text PDFBMC Gastroenterol
January 2025
Cardiovascular Epidemiology Research Center, Rajaie Cardiovascular Institute, Tehran, Iran.
Background: Cholangiocarcinoma (CCA) is a type of cancer that develops in the biliary tract. CCA accounts for 10% of primary hepatic cancers and is characterized by its aggressive nature and poor prognosis. This systematic review and meta-analysis aims to assess the prognostic value of the novel hepatic function assessment measure known as albumin-bilirubin (ALBI) grade in patients with CCA.
View Article and Find Full Text PDFTransfus Clin Biol
January 2025
Department of Community Medicine, SCB Medical College & Hospital, Cuttack, Odisha, India. Electronic address:
Objectives: Neonatal hyperbilirubinemia, or newborn jaundice, is a common condition caused by high bilirubin levels. Blood group incompatibility between mother and baby is a major cause. This study examined the link between different blood group incompatibilities and their management in newborns with jaundice.
View Article and Find Full Text PDFPoult Sci
January 2025
Department of Preventive Veterinary Medicine, College of Veterinary Medicine, Shandong Agricultural University, Taian, 271017, China; Shandong Provincial Key Laboratory of Zoonoses, Shandong, Taian, 271017, China. Electronic address:
Duck circovirus (DuCV) infected multiple breeds of ducks and was widespread in duck factories worldwide. Infected ducks exhibited feathering disorder, growth retardation and immunosuppression, which lead to secondary infection with other pathogens easily. But till now, there has been little research on the study of DuCV due to the absence of appropriate cultural measures.
View Article and Find Full Text PDFArq Bras Cir Dig
January 2025
Santa Casa de Misericórdia de Porto Alegre - Porto Alegre (RS), Brazil.
Background: Cholangiocarcinoma (CCA) is a rare neoplasm, with high mortality, originating in the bile ducts. Its incidence is higher in Eastern countries due to the endemic prevalence of liver parasites. Factors such as metabolic syndrome, smoking, and pro-inflammatory conditions are also linked to the disease.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!